Compare Alcon AG (ALC) vs Banco Bilbao Vizcaya Argentaria SA (BBVA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Banco Bilbao Vizcaya Argentaria SA — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Banco Bilbao Vizcaya Argentaria SA trades at $25.3 (market cap $143.90B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 4.4× Alcon AG's market cap, and Banco Bilbao Vizcaya Argentaria SA pays the higher dividend (4.13%). Which is the better fit depends on your goals.
| ALC | BBVA | |
|---|---|---|
Market Cap | $32.69B | $143.90B |
Sector | Health | Financials |
52-Week High | $92.22 | $26.14 |
52-Week Low | $62.02 | $14.73 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
BBVA trades at $26.07, up 1.84% today, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 26.51% net income margin and 18.67% ROE, while recent Q1 2026 earnings beat expectations. Positive sentiment is driven by analyst upgrades and news highlighting European bank outperformance and strategic partnerships, though regulatory scrutiny in Spain presents a headwind.
The outlook remains favorable given solid earnings growth, high ROE, and a majority analyst buy rating. Key risks include antitrust investigations and volatile cash flows, but the stock's reasonable P/E of 12.61 and dividend yield offer value. Upside is contingent on sustained loan growth and execution in key markets like Mexico.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →
